Advertisement

Klinische Ergebnisse der «Drug-eluting»-Ballonangioplastie

Zusammenfassung

Die konventionelle Angioplastie mit unbeschichteten PTA-Kathetern ist durch Restenose-Raten von ca. 50 % nach 1 Jahr limitiert. Ein möglicher Ansatz zur Ergebnisoptimierung ist der ergänzende Einsatz medikamentenbeschichteter PTA-Katheter («DCB»). Bei der Anwendung in der Oberschenkeletage konnten die getesteten DCB einen geringen Lumenverlust 6 Monate nach Intervention zeigen. Nach 12 Monaten zeigte sich eine höhere Freiheit von Reintervention nach DCB-Behandlung. Bei der Behandlung von In-Stent-Restenosen gibt es erste Hinweise auf Vorteile der DCB. Weitere Forschung in diesem Bereich wird die Evidenz noch festigen müssen. Keine Behandlungsvorteile des DCB zeigten sich bisher in der Unterschenkeletage. Langzeitergebnisse fehlen noch für alle 3 oben genannten Behandlungsszenarien. Insbesondere der Aspekt eines möglichen «late catch-up», d. h. des Verlustes des initialen Behandlungsvorteils, ist bisher noch nicht geklärt.

Literatur

  1. Chowdhury MM, McLain AD, Twine CP (2014) Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev(6) CD006767. doi:10.1002/14651858.CD006767.pub3
  2. Connors G, Todoran TM, Engelson, et al. (2011) Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv 77(7): 1055–1062. doi:10.1002/ccd.22802CrossRefGoogle Scholar
  3. Fanelli F, Cannavale A, Boatta E, et al. (2012) Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther 19(5): 571–580. doi:10.1583/JEVT-12-3926MR.1CrossRefGoogle Scholar
  4. Fanelli F, Cannavale A, Corona M, et al. (2014) The «DEBELLUM» – lower limb multilevel treatment with drug eluting balloon – randomized trial: 1-year results. J Cardiovasc Surg (Torino) 55(2): 207–216Google Scholar
  5. Grotti S, Liistro F, Angioli P, et al. (2016) Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study. J Endovasc Ther 23(1): 52–57. doi:10.1177/1526602815614555CrossRefGoogle Scholar
  6. Jia X, Zhang J, Zhuang B, et al. (2016) Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial. JACC Cardiovasc Interv 9(18): 1941–1949. doi:10.1016/j.jcin.2016.06.055PubMedGoogle Scholar
  7. Kinstner CM, Lammer J, Willfort-Ehringer A, et al. (2016) Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. JACC Cardiovasc Interv 9(13): 1386–1392. doi:10.1016/j.jcin.2016.04.012PubMedGoogle Scholar
  8. Krankenberg H, Tubler T, Ingwersen M, et al. (2015) Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation 132(23): 2230–2236. doi:10.1161/CIRCULATIONAHA.115.017364CrossRefGoogle Scholar
  9. Laird JR, Schneider PA, Tepe G et al. (2015) Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. J Am Coll Cardiol 66(21): 2329–2338. doi:10.1016/j.jacc.2015.09.063CrossRefGoogle Scholar
  10. Liistro F, Angioli P, Porto I, et al. (2014) Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther 21(1): 1–8. doi:10.1583/13-4420R.1CrossRefGoogle Scholar
  11. Liistro F, Grotti S, Porto I, et al. (2013) Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 6(12): 1295–1302. doi:10.1016/j.jcin.2013.07.010PubMedGoogle Scholar
  12. Liistro F, Porto I, Angioli P, et al. (2013) Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation 128(6): 615–621. doi:10.1161/CIRCULATIONAHA.113.001811CrossRefGoogle Scholar
  13. Rosenfield K, Jaff MR, White CJ, et al. (2015) Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med 373(2): 145–153. doi:10.1056/NEJMoa1406235CrossRefGoogle Scholar
  14. Scheinert D, Duda S, Zeller T, et al. (2014) The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 7(1): 10–19. doi:10.1016/j.jcin.2013.05.022PubMedGoogle Scholar
  15. Scheinert D, Scheinert, S, Sax, J, et al. (2005) Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 45(2): 312–315. doi:10.1016/j.jacc.2004.11.026CrossRefGoogle Scholar
  16. Scheinert D, Schulte KL, Zeller T, et al. (2015) Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther 22(1): 14–21. doi:10.1177/1526602814564383CrossRefGoogle Scholar
  17. Schmidt A, Piorkowski M, Gorner H, et al. (2016) Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry. JACC Cardiovasc Interv 9(7): 715–724. doi:10.1016/j.jcin.2015.12.267PubMedGoogle Scholar
  18. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S (2015) Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv 86 (2):278–286CrossRefGoogle Scholar
  19. Schroeder H, Werner M, Meyer DR, Reimer P, Kruger K, Jaff MR, Brodmann M, Investigators IER (2017) Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon). Circulation 135 (23):2227–2236CrossRefGoogle Scholar
  20. Tepe G, Laird J, Schneider P, et al. (2015) Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 131(5): 495–502. doi:10.1161/CIRCULATIONAHA.114.011004CrossRefGoogle Scholar
  21. Tepe G, Schnorr B, Albrecht T, et al. (2015) Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv 8(1 Pt A): 102–108. doi:10.1016/j.jcin.2014.07.023PubMedGoogle Scholar
  22. Tepe G, Zeller T, Albrecht T, et al. (2008) Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 358(7): 689–699. doi:10.1056/NEJMoa0706356CrossRefGoogle Scholar
  23. Tosaka A, Soga Y, Iida O, et al. (2012) Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 59(1): 16–23. doi:10.1016/j.jacc.2011.09.036CrossRefGoogle Scholar
  24. Werk M, Albrecht T, Meyer DR, et al. (2012) Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 5(6): 831–840. doi:10.1161/CIRCINTERVENTIONS.112.971630Google Scholar
  25. Werk M, Langner S, Reinkensmeier B, et al. (2008) Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118(13): 1358–1365. doi:10.1161/CIRCULATIONAHA.107.735985CrossRefGoogle Scholar
  26. Zeller T, Baumgartner I, Scheinert D, et al. (2014) Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 64(15): 1568–1576. doi:10.1016/j.jacc.2014.06.1198CrossRefGoogle Scholar
  27. Zeller T, Beschorner U, Pilger E, et al. (2015) Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK’S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 8(12): 1614–1622. doi:10.1016/j.jcin.2015.07.011PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2018

Authors and Affiliations

  1. 1.Abteilung VIII - RadiologieBundeswehrkrankenhaus UlmUlmDeutschland
  2. 2.Institut für Diagnostische und Interventionelle RadiologieUniversitätsklinikum JenaJenaDeutschland

Personalised recommendations